Phase 1 Study of the Selective c-MET Inhibitor, HS-10241, in Patients With Advanced Solid Tumors
Lists
Only you see this
Abstract
The selective c-MET inhibitor HS-10241 was well tolerated and had clinical activity in advanced NSCLC, especially in patients with positive MET. Furthermore, this study expounds on the therapeutic potential of HS-10241 in patients with cancer.
BibTeX
@inproceedings{dong2022phase,
author = {Xiaorong Dong and Xingya Li and Jianhua Chen and Shenglin Ma and Deguang Mu and Jie Hu and Shun Lü},
title = {{Phase 1 Study of the Selective c-MET Inhibitor, HS-10241, in Patients With Advanced Solid Tumors}},
booktitle = {JTO},
year = {2022},
doi = {10.1016/j.jtocrr.2022.100449},
}Loading related content...